Literature DB >> 8735173

Relaxant effect of human brain natriuretic peptide on human artery and vein tissue.

A A Protter1, A M Wallace, V A Ferraris, R E Weishaar.   

Abstract

Brain natriuretic peptide (BNP) is a cardiac-derived peptide hormone with cardiovascular and renal actions that is structurally and functionally related to atrial natriuretic peptide (ANP). Previous studies using rat vascular tissue have demonstrated a direct vasorelaxant effect of BNP. However, species-specific potency issues have precluded an accurate measurement of the effect of human BNP. This report demonstrates the vasorelaxant effects of human BNP on human vascular tissue prepared from internal mammary artery and saphenous vein samples. The vasorelaxant effect of human BNP is compared to the other members of the natriuretic peptide family, human ANP and C-type natriuretic peptide (CNP). With regard to potency and magnitude of effect, human BNP and human ANP were similar in relaxing arterial tissue preconstricted with endothelin-1 (BNP ED50 = 1.9 nmol/L and ANP ED50 = 1.8 nmol/L) or phenylephrine (BNP ED50 = 10 nmol/L and ANP ED50 = 19 nmol/L), while CNP was significantly less effective. All three natriuretic peptides exhibited weak venodilating action. These data demonstrate that human BNP is a potent inhibitor of the vasoconstrictive actions of endothelin-1 and the alpha-adrenergic agonist phenylephrine on isolated human artery tissue preparations.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8735173     DOI: 10.1016/0895-7061(95)00435-1

Source DB:  PubMed          Journal:  Am J Hypertens        ISSN: 0895-7061            Impact factor:   2.689


  12 in total

Review 1.  Membrane guanylyl cyclase receptors: an update.

Authors:  David L Garbers; Ted D Chrisman; Phi Wiegn; Takeshi Katafuchi; Joseph P Albanesi; Vincent Bielinski; Barbara Barylko; Margaret M Redfield; John C Burnett
Journal:  Trends Endocrinol Metab       Date:  2006-06-30       Impact factor: 12.015

Review 2.  Benefit-risk assessment of nesiritide in the treatment of acute decompensated heart failure.

Authors:  Clyde W Yancy
Journal:  Drug Saf       Date:  2007       Impact factor: 5.606

Review 3.  Nesiritide: a review of its use in acute decompensated heart failure.

Authors:  Gillian M Keating; Karen L Goa
Journal:  Drugs       Date:  2003       Impact factor: 9.546

4.  A prospective evaluation of nesiritide in the treatment of pediatric heart failure.

Authors:  J L Jefferies; S W Denfield; J F Price; W J Dreyer; C J McMahon; M A Grenier; J J Kim; V V Dimas; S K Clunie; B S Moffett; A C Chang; T I Wann; E O Smith; J A Towbin
Journal:  Pediatr Cardiol       Date:  2006 Jul-Aug       Impact factor: 1.655

Review 5.  Practical application of human B-type natriuretic peptide as a therapeutic intervention in the perioperative setting.

Authors:  David S Feldman; Benjamin Sun
Journal:  Heart Fail Rev       Date:  2004-07       Impact factor: 4.214

6.  Physiological antagonism of endothelin-1 in human conductance and resistance coronary artery.

Authors:  K E Wiley; A P Davenport
Journal:  Br J Pharmacol       Date:  2001-06       Impact factor: 8.739

7.  Comparison of vasodilators in human internal mammary artery: ghrelin is a potent physiological antagonist of endothelin-1.

Authors:  Katherine E Wiley; Anthony P Davenport
Journal:  Br J Pharmacol       Date:  2002-08       Impact factor: 8.739

8.  N-terminal pro-brain natriuretic peptide (NT-proBNP) release in children with vagus nerve stimulation. A prospective case series.

Authors:  Markus Rauchenzauner; Edda Haberlandt; Martin Ortler; Tobias Tatarczyk; Markus Laimer; Eugen Trinka; Gerhard Luef
Journal:  J Neurol       Date:  2008-06-27       Impact factor: 4.849

Review 9.  Molecular and physiological effects of nesiritide.

Authors:  S Reichert; A Ignaszewski
Journal:  Can J Cardiol       Date:  2008-07       Impact factor: 5.223

10.  Pharmacodynamics of a novel designer natriuretic peptide, CD-NP, in a first-in-human clinical trial in healthy subjects.

Authors:  Candace Y W Lee; Horng H Chen; Ondrej Lisy; Suzanne Swan; Courtney Cannon; Hsiao D Lieu; John C Burnett
Journal:  J Clin Pharmacol       Date:  2009-04-24       Impact factor: 3.126

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.